Biomarkers for predicting the response to checkpoint inhibitors
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsToshiki Iwai, Masamichi Sugimoto
Life of this patent
Estimating the term…
Abstract
The invention provides biomarkers for predicting the response to checkpoint inhibitors. The inventors demonstrate that a PD-1/PD-L1 inhibitor exerts antitumor activity against tumor with low PD-L1 expression and immune-desert phenotype through blocking PD-L1 in the lymph nodes. The invention provides novel combinations of intratumoral markers for antigen cross-presenting cells and T cell chemokines which are expected to be superior efficacy-predicting biomarkers compared to existing methods.
Claims15
A method of identifying a patient who has or is suspected of having a cancer which is responsive to a therapy comprising administration of an effective amount of a PD-1/PD-L1 inhibitor, wherein the method comprises:
- detecting (i) and (ii) below in a sample from the patient:
- (i) at least one marker for estimating an intratumoral amount of dendritic cells (DCs) having cross-presentation ability to CD8-positive T cells;
- and
- (ii) at least one chemokine that accumulates effector T cells in tumor.
A method of predicting the therapeutic effect of a PD-1/PD-L1 inhibitor on a cancer patient, wherein the method comprises:
- detecting (i) and (ii) below in a sample from the patient:
- (i) at least one marker for estimating an intratumoral amount of dendritic cells (DCs) having cross-presentation ability to CD8-positive T cells;
- and
- (ii) at least one chemokine that accumulates effector T cells in tumor.
Dependencies are inferred from the claim text.